No Established Independent VTE Association for Either Eszopiclone or Gabapentin as Monotherapy
Neither eszopiclone (Lunesta) nor gabapentin has a documented independent association with venous thromboembolism (VTE) when used alone based on current FDA labeling and available evidence.
Eszopiclone (Lunesta) - No VTE Signal
The FDA-approved prescribing information for eszopiclone does not list VTE, deep vein thrombosis, or pulmonary embolism as adverse events 1. The drug label's warnings section focuses on:
- Complex sleep behaviors (sleep-driving)
- CNS depression effects
- Anaphylactic reactions
- Psychiatric/behavioral changes
No mention of thrombotic risk appears anywhere in the official drug labeling, which would be required if VTE were a recognized adverse effect.
Gabapentin - No VTE Signal
Similarly, gabapentin does not carry VTE warnings or associations in standard prescribing information. The drug is primarily used for neuropathic pain and seizure disorders, with well-characterized adverse effects that do not include thrombotic events.
Critical Drug-Drug Interaction Signal
However, the combination of gabapentin with eszopiclone (or other benzodiazepines) shows a concerning VTE signal. A 2026 self-controlled case series analysis identified potential drug interaction signals, with gabapentin combined with eszopiclone showing a ratio of incidence rate ratio of 1.92-3.57 2. Notably, 80% of the identified signals involved concurrent gabapentin use, suggesting this medication may act as a potentiating factor when combined with sedative-hypnotics.
Benzodiazepine Class Association
While eszopiclone is technically a non-benzodiazepine hypnotic, the broader class of benzodiazepines and related drugs (BZDRs) does show VTE association. A 2025 meta-analysis found BZDR exposure associated with increased VTE risk (OR 1.47,95% CI 1.19-1.7) 3. This suggests the risk may be class-related rather than specific to individual agents.
Clinical Implications
- Monotherapy: Neither drug requires specific VTE prophylaxis considerations when used alone
- Combination therapy: Exercise heightened vigilance when prescribing gabapentin with eszopiclone or benzodiazepines, particularly in patients with baseline VTE risk factors (immobility, cancer, prior VTE, obesity, age >40)
- Risk stratification: The gabapentin-eszopiclone interaction may increase relative VTE rate up to 3.5-fold 2, warranting consideration of alternative agents in high-risk patients
The evidence suggests these medications are safe from a VTE perspective when used individually, but their combination—particularly gabapentin with sedative-hypnotics—requires careful risk-benefit assessment.